

## Correction: Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma

In this article (Mol Cancer Res 2015;13:775–83), which appeared in the April 2015 issue of *Molecular Cancer Research* (1), the grant support section was missing a funding source. The corrected grant support section is below. The authors regret the error.

This work was supported by the Lombardy Region (ID14546A) and the Italian Association for Cancer Research (AIRC 2013 IG-14249).

### Reference

1. Ceccon M, Mologni L, Giudici G, Piazza R, Pirola A, Fontana D, et al. Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma. *Mol Cancer Res* 2015;13:775–83.

---

Published OnlineFirst September 29, 2015.

doi: 10.1158/1541-7786.MCR-15-0277

©2015 American Association for Cancer Research.

# Molecular Cancer Research

## Correction: Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK–Positive Anaplastic Large Cell Lymphoma

*Mol Cancer Res* Published OnlineFirst September 29, 2015.

**Updated version** Access the most recent version of this article at:  
doi:[10.1158/1541-7786.MCR-15-0277](https://doi.org/10.1158/1541-7786.MCR-15-0277)

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://mcr.aacrjournals.org/content/early/2015/09/28/1541-7786.MCR-15-0277>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.